The next evolution of targeted cancer drugs
OUR MISSION
To overcome resistance of cancer to existing kinase inhibitors
OUR VISION
Improving the outcome of treatment of cancers through technology and collaboration

DNA SEQ is a lean organization, leveraging exceptional industry partners and guided by world class advisors.
​
Numerous members of our team pioneered the creation of the ATP competitive kinase inhibitor industry. We have demonstrated experience at every level in bringing drugs to FDA approval.
We are lean because we understand that what is required is just an extension of the same process used to discover ATP competitive kinase inhibitors. Sounds simple? It is and it isn't.
​
Our latest discovery will transform cancer treatment and become the gold standard of targeted therapies of the future.
Executive Team

Janusz Sowadski, Ph.D.
Chief Science Officer, Founder & Director
Janusz Maria Sowadski, Ph.D., is a scientist and entrepreneur who discovered the first crystal structures of key oncogenic signaling molecule-phosphatases and kinases. His numerous crystallographic and modeling discoveries in the field of protein kinases have opened the market for personalized targeted oncology treatments. Most notably, in 1991, he discovered the first three-dimensional structure of protein kinase (PKA), which led to the development of Gleevec®, the world’s first orally-administered targeted oncology drug. Janusz M. Sowadski is the recipient of US Supercomputing Award (Wherle Award). He is an author of over sixty articles (cited 7294 times) and nine patents and patent applications.

Andy Nappin
Chief Executive Officer
​
Over 20 years in professional services and supply chain industries combining experience working at Deloitte in the M&A corporate tax division, an equity capital markets analyst as well as working as the national sales and marketing manager for a division of the Swire Group before starting his own consulting business. He has advised a number of small start up companies focused in the health and wellness industries. After recovering from several years of chronic illness due to Malaria and Typhoid fever, he has now focused his life goals to help people gain better access to medical solutions that can be leveraged by technology. Andy has collaborated with large multinationals to further their supply chain logistics efficiencies, implementing value added strategies and long term sustainability.
Board of Directors

Stuart Siegel, MD
Board Chair
Stuart E. Siegel, M.D., was the Founding Director of the Children’s Center for Cancer and Blood Diseases and the Center for International Health at CHLA, and the first holder of the Stuart E. Siegel, M.D. Endowed Chair in Pediatric Oncology at Keck School of Medicine of USC. He was a Professor of Pediatrics and Medicine at the Keck School of Medicine of USC as well as the Director of the Center for Global Health at Children’s Hospital Los Angeles (CHLA). He led one of the largest academic Pediatric Hematology-Oncology programs in the nation and among many innovative accomplishments, developed the first comprehensive program for the psychosocial aspects of pediatric cancer.

Thomas Wheeler, MD
Board Member & Founding Advisor
Dr. Thomas M. Wheeler, MD, is the former W.L. Moody, Jr. Chair of the Department of Pathology & Immunology at Baylor College of Medicine and is presently Distinguished Emeritus Professor at BCM. He serves as a member of the permanent editorial board of several pathology journals and is on the Editorial Advisory Board at Medscape, LLC., where he is editor-in-chief of Medscape Reference, Pathology. Dr. Wheeler is board certified in anatomic pathology, clinical pathology, and cytopathology and has served 40+ years in academia, with special focus on clinicopathologic correlations in cancer, particularly prostate cancer. Dr. Wheeler is currently Head of Surgical Pathology and Cytopathology at Sagis Diagnostics, PLLC.

Eric Ladizinsky
Board Member
Eric Ladizinsky is a physicist, Co-founder, and Chief Scientist of D-Wave Systems (The Quantum Computing Company). He was primarily responsible for the company’s transition, in 2004, from an IP based company to a technology development company, advocating an aggressive, mini Manhattan Project-like approach to building quantum computers. This included building of interdisciplinary science/engineering teams, establishing a rapid prototyping infrastructure and culture and designing/developing of D-Wave’s, world leading, Superconducting Integrated Circuit capability underlying D-Wave’s quantum processors. He currently runs R&D and the superconducting fabrication groups at D-Wave.

Janusz Sowadski PH.D.
Chief Science Officer, Founder & Director
Janusz Maria Sowadski, Ph.D., is a scientist and entrepreneur who discovered the first crystal structures of key oncogenic signaling molecule-phosphatases and kinases. His numerous crystallographic and modeling discoveries in the field of protein kinases have opened the market for personalized targeted oncology treatments. Most notably, in 1991, he discovered the first three-dimensional structure of protein kinase (PKA), which led to the development of Gleevec®, the world’s first orally-administered targeted oncology drug. Janusz M. Sowadski is the recipient of US Supercomputing Award (Wherle Award). He is an author of over sixty articles (cited 7294 times) and nine patents and patent applications.
Scientific Advisory Board

Lisa Haile Ph.D.
SAB Chair
Dr. Lisa Haile is a partner at DLA Piper and concentrates on patent protection. Dr. Haile has special technical experience in molecular biology, immunology, cell biology, regenerative medicine including ESCs, iPSCs, pSCs, diagnostics, therapeutics, theranostics, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Haile is a member of DLA Piper’s Executive Committee.

Brian Druker M.D.
SAB Member
​
Dr. Brian Druker is an Investigator of the Howard Hughes Medical Institute, Director of the Oregon Health & Science University (OHSU) Cancer Institute, and JELD-WEN Chair of Leukemia Research at OHSU. Dr. Druker began his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. His work was instrumental in the development of Gleevec (imatinib), a drug that targets the molecular defect in chronic myeloid leukemia (CML). After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML and gastrointestinal stromal tumors (GIST). His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the Lasker Prize, the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology’s Dameshek Prize, the American Cancer Society’s Medal of Honor, the Kettering Prize from General Motors Cancer Research Foundation, and the David A. Karnofsky Award from the American Society of Clinical Oncology. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, and the National Academy of Sciences in 2007. Anatomy of a Breakthrough in Targeted Cancer Treatments

Grace Gill, Ph.D.
SAB Member
Grace Gill, Ph.D. has a track record of research advances in molecular mechanisms of gene expression and signal transduction. From her seminal work on the modularity of transcription factors to later studies revealing how post-translation modification impacts activity of proteins that regulate gene expression, her work has led to new concepts and approaches across fields. She has held faculty appointments at Harvard Medical School and at Tufts University School of Medicine. She has broad knowledge of the cellular and molecular pathways underlying cancer initiation and progression and she was a Visiting Scientist at Cell and Molecular Cell and a Senior Scientific Editor at Cell Reports, where she worked to promote clear communication of new findings from diverse fields of science.

Tony Hunter, Ph.D.
SAB Member & Founding Advisor
​
Tony Hunter Ph.D. made the seminal discovery, more than three decades ago, that the addition and subtraction of phosphate molecules to proteins on tyrosine, one of the 20 amino acids, allows cells to control when key proteins are on standby and when they are active. In cancers, he went on to show that growth was switched into an always-on mode by the malfunctions of these phosphates. Since then, his lab has led the field in understanding how chemical additions to proteins control the cell cycle and growth. Tony Hunter uses cutting-edge molecular, genetic and cell biology techniques to probe how these programs interact with each other.

Walter Gilbert Ph.D.
Mentor
Walter (Wally) Gilbert,Ph.D., is a renowned scientist who was awarded the 1980 Nobel Prize in Chemistry for his discovery of a method for rapid DNA sequencing. His forty-year academic career at Harvard University was marked by many discoveries, including messenger RNA, genetic repressors, DNA sequencing, and the first expression of insulin in bacteria. Dr. Gilbert is the Carl M. Loeb University Professor Emeritus at Harvard University. In 1978 Dr. Gilbert co-founded Biogen, the world’s oldest independent biotechnology company. As CEO, Dr. Gilbert oversaw Biogen’s Initial Public Offering in 1983.

Robert Suto
Founding Advisor
​
Robert K. Suto, PhD, President, XTAL As a biochemist with a thorough knowledge of structure-guided drug discovery, Dr. Suto has now been involved, through XTAL, in the discovery and development projects of over sixty companies. During post-doctoral studies with Professor Karolin Luger at Colorado State University, he conducted X-ray crystallography studies of nucleosome core particles containing histone variants and DNA binding polyamide ligands. Dr. Suto is currently serving as a co-chair of MassBio’s Drug Discovery Working Group. The mission is to provide a forum for drug discovery and early development executives, managers and researches to exchange ideas, information and resources in order to expedite the discovery and validation of new targets and drugs.

Alan Vaughan, Ph.D.
SAB Member
Dr. Vaughan’s single site catalyst discoveries in the ‘90s produced high performance, lower carbon footprint polyethylenes at global scale that are now ubiquitous in every day life which added $100M+ annually in additional profits to ExxonMobil Chemical in the early 2000s. He has filed over 30 US patent families. Subsequently he served in a variety of business and technical roles focused on new business development and startup monetization that led to the acquisition of Materia Inc., founded by Nobel laureate Prof. Robert Grubbs, and the formation of major programs focused on new carbon rich materials such as carbon fiber and Lithium ion battery anode materials with lower carbon footprints. He has negotiated numerous technology licensing, acquisition, and partnership agreements including his role as the lead technology negotiator in the world’s largest blue hydrogen project announced recently. Dr Vaughan’s work at DNA SEQ has provided immediate identification of high probability molecules contained in DNA SEQ’s patent estate that we intend to progress as lead molecules in addition to providing insights into the Company’s patent and monetization strategies. In addition Dr Vaughan has overseen interactions with our contract research partners and guided our program of work for future target selection.
Algorithm Team

Davide Moiani, Ph.D.
Consulting Crystallographer
​
Dr. Davide Moiani was a key member of the team that integrated the more than 60 million XYZ atomic coordinates in the DNA SEQ crystal structures library with the algorithm. In 2008 Davide obtained his doctorate in Chemical Engineering at Politecnico di Milano (Italy) and did his post doc at Scripps Research Institute in La Jolla California. Dr Moiani currently is a member of Prof John Tainer’s group at MD Anderson. Davide is co-author of DNA SEQ’s 1 patent and 2 White Papers. Davide Moiani currently works at the Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center. Davide does research in Physical Chemistry, Chemical Biology and Biochemistry.

Alexander Melton
Pattern Matching and Machine Learning and SAB member
​
Mr Melton developed a disability assessment platform for commercial workplaces in Oklahoma and was an Android Engineer at One20. He was a consultant at Booz Allen Hamilton, USAF for the development of the current United States Air Force weapon systems life cycle management program and the executive management process. Sole developer of the web application responsible for organizing temporary domestic relocation of USAF troops. Software Engineer at Textron Aviation, Cessna as project lead on their UAV control systems. Mr Melton has identified additional tools to develop new algorithms for DNA SEQ that have the potential to expand our business case into areas beyond cancer drug discovery which will commence in 2024.

Dmytro Korenkevych
Deep Learning & Reinforcement Learning Researcher
​
Dmytro Korenkevych, Ph.D., is a deep learning and a reinforcement learning researcher. He received his B.S. and M.S. from Moscow Institute of Physics and Technology and his PhD from the University of Florida. His PhD thesis focuses on machine learning approaches to problems in biomedical domain. After graduation, Dmytro joined D-Wave Systems as a machine learning researcher. There, he designed machine learning systems that exploit D-Wave quantum hardware to train energy-based learning models. Currently Dmytro is a reinforcement learning researcher at Kindred, where he develops reinforcement learning algorithms and designs deep reinforcement learning systems with application to physical robots

Learn about DNA SEQ's discoveries
DNA SEQ is far and away leading the scientific field. We are positioned with the most comprehensive scientific opportunity which includes:
-
The largest pipeline of targets - 303 genuine drug candidates
-
Targeting 6 different cancer indications
-
The worlds foremost experts, many who were involved in creating the ATP competitive kinase inhibitor market place
-
Clinical partner already place with the Knight Cancer Institute
-
World class CRO with experience in taking small molecule drugs to market
​